Avicanna (TSE:AVCN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avicanna Inc., a biopharmaceutical company specializing in cannabinoid-based products, has announced significant growth with Q2 2024 revenues soaring to $6.1 million, marking an 85% increase from the previous year. The company also reported the successful completion of two real-world evidence trials for treatments targeting Epidermolysis Bullosa and musculoskeletal pain, reflecting a strong emphasis on research and development in the medical cannabis field.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.